id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S8069 R24575 |
Trivedi (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2018 | Spontaneous fetal loss (both spontaneous abortion before 20 weeks of gestation and stillbirths occurring after 20 weeks of gestation) | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.08 [0.27;4.27] C excluded (control group) |
5/56 4/48 | 9 | 56 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8060 R24566 |
Trivedi (Oxcarbazepine) (Controls unexposed, sick), 2018 | Spontaneous fetal loss (both spontaneous abortion before 20 weeks of gestation and stillbirths occurring after 20 weeks of gestation) | 1st trimester | prospective cohort | unexposed, sick | Adjustment: Yes | 7.53 [1.54;36.89] | 5/56 5/178 | 10 | 56 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7760 R22966 |
Vajda (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2018 | Intrauterine foetal death | throughout pregnancy | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.46 [0.18;11.73] C excluded (control group) |
1/19 14/382 | 15 | 19 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7754 R22960 |
Vajda (Oxcarbazepine) (Controls unexposed, sick), 2018 | Intrauterine foetal death | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 8.94 [0.53;137.30] | 1/19 1/170 | 2 | 19 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7816 R23215 |
Tomson (Oxcarbazepine), 2015 | Intrauterine death | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.08 [0.67;1.72] C | 22/262 150/1,910 | 172 | 262 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 3.13 [0.62;15.80] | 184 | 337 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Oxcarbazepine) (Controls unexposed, sick; 2: Oxcarbazepine) (Controls unexposed, sick; 3: Oxcarbazepine;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 8069, 7760